Literature DB >> 22348971

Valvular disease: TAVR is cost-effective in the USA and UK.

Gregory B Lim.   

Abstract

Entities:  

Year:  2012        PMID： 22348971     DOI： 10.1038/nrcardio.2012.20

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement.

Authors:  Maureen Watt; Stuart Mealing; James Eaton; Nicolo Piazza; Neil Moat; Pascale Brasseur; Stephen Palmer; Rachele Busca; Mark Sculpher
Journal:  Heart       Date:  2011-11-10       Impact factor: 5.994

2.  Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B).

Authors:  Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Yang Lei; Katherine Vilain; Joshua Walczak; Susheel K Kodali; John M Lasala; William W O'Neill; Charles J Davidson; Craig R Smith; Martin B Leon; David J Cohen
Journal:  Circulation       Date:  2012-02-03       Impact factor: 29.690
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.